Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver

This study investigates the impact of surgical resection compared to palliative care in patients with oligometastatic pancreatic cancer limited to the liver. Specifically, it examines whether surgery after stable disease or response to chemotherapy can improve survival and quality of life. The international, multicenter randomized trial will recruit 56 patients, assigning them to either surgical resection (including tumor and liver metastases) or ongoing palliative care with chemotherapy. Stratification by performance status, tumor markers, and tumor location will ensure balanced study groups.

Trial Details

NCT ID

NCT06690528

Phase

PHASE2

Sponsor

Azienda Ospedaliera di Padova

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Surgical resection of both the primary tumor and liver metastases

Locations (sample)

Padova, Italy, Italy|44.38225,11.14261

Key Eligibility Criteria

Adult patients aged ≥18 years and ≤75 years (at diagnosis).
Cytologically or histologically confirmed pancreatic adenocarcinoma either resectable or borderline resectable (at diagnosis) according to National…
Synchronous oligometastatic disease (at diagnosis), defined as a limited number of radiologically documented liver metastases (up to 3 lesions).
No evidence of extrahepatic metastases (at diagnosis.)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →